NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2301.30 18.40 (0.81%)

28.38% Gain from 52W Low

740.6K NSE+BSE Volume

NSE 13 Jul, 2026 3:31 PM (IST)

64,942.9

Market Cap

High in industry

Beta 1Year

Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

09 Jul 2026

2301.30

0.81%

Glenmark Pharmaceuticals Ltd. – Q1FY27 Preview:

Accumulate: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 16.8% / 86.1% / 111.8% for the period of FY26-FY28.

Deven Choksey released a Accumulate report for Glenmark Pharmaceuticals Ltd. with a price target of 2410.0 on 09 Jul, 2026.

Glenmark Pharmaceuticals Ltd.

01 Jul 2026

2301.30

0.81%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives. In Q4FY26, Glenmark's normalized revenue grew 11.1% YoY to Rs. 3,616cr, driven...

Deven Choksey released a Accumulate report for Glenmark Pharmaceuticals Ltd. with a price target of 2410.0 on 09 Jul, 2026.

Glenmark Pharmaceuticals Ltd.

10 Jun 2026

2301.30

0.81%

Innovation Business Can Become a Major Value Driver

Accumulate: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Outlook remains positive, supported by multiple growth drivers across its innovation, specialty, and US generics businesses. Continued scaling of Ryaltris, commercialization of new respiratory products in the US, and the restart of injectable operations are expected to support earnings growth over the next few years.

Glenmark Pharmaceuti.. has an average target of 2291.25 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

01 Jun 2026

2301.30

0.81%

A mixed quarter; US/DF underperforms for the quarter

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered lower-than-expected financial performance for the quarter. While revenue was in line with our estimate, EBITDA was a 7% miss.

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2301.30

0.81%

Sustainability of cost curbs key to boost earnings growth

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark’s Q3FY26 revenue growth was led by India biz, while US growth was muted post adjusted for USD 18mn of milestone income. Gross margin was lower by 259bps YoY due to unfavourable product and geographical mix, though cost curbs drove 131bps expansion in EBITDA margin.

Glenmark Pharmaceuti.. has an average target of 2291.25 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2301.30

0.81%

Mixed quarter; domestic strengthens

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted largely in-line financial performance in 3QFY26. The quarterly performance was driven by a healthy revival in the domestic formulation (DF) business, out-licensing income related to ISB2001, and better performance in emerging markets.

Number of FII/FPI investors increased from 422 to 436 in Mar 2026 qtr.

Glenmark Pharmaceuticals Ltd.

18 Nov 2025

2301.30

0.81%

Exceptional Q2 buoyed by ISB-2001 income and sharp margin expansion.

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300.

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

17 Nov 2025

2301.30

0.81%

Tough quarter led by GST shock and operational reset

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered a miss on 2QFY26 earnings, adjusted for a one-time upfront payment received from Abbvie. The miss was largely driven by a severe impact on the domestic formulation (DF) business following the GST transition.

Glenmark Pharmaceuti.. has an average target of 2291.25 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

09 Sep 2025

2301.30

0.81%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives....

Deven Choksey released a Accumulate report for Glenmark Pharmaceuticals Ltd. with a price target of 2410.0 on 09 Jul, 2026.

Is Glenmark Pharmaceuticals Ltd. worth buying?

581 Votes:

Buy 79.52%

Sell 13.6%

Hold 6.88%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf